IRIS
BUTTINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.003
AS - Asia 5.733
EU - Europa 3.926
SA - Sud America 825
AF - Africa 264
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.854
SG - Singapore 2.084
CN - Cina 1.529
VN - Vietnam 903
IT - Italia 799
IE - Irlanda 729
BR - Brasile 636
SE - Svezia 481
HK - Hong Kong 449
FI - Finlandia 378
DE - Germania 357
FR - Francia 306
NL - Olanda 221
ZA - Sudafrica 178
TR - Turchia 165
UA - Ucraina 143
GB - Regno Unito 138
IN - India 113
RU - Federazione Russa 98
AR - Argentina 82
CA - Canada 81
KR - Corea 79
BD - Bangladesh 78
AT - Austria 76
ID - Indonesia 50
MX - Messico 48
ES - Italia 46
JP - Giappone 45
IQ - Iraq 43
PL - Polonia 30
BE - Belgio 29
AU - Australia 28
PK - Pakistan 27
TW - Taiwan 26
EC - Ecuador 25
CO - Colombia 24
MA - Marocco 22
PY - Paraguay 21
PH - Filippine 20
CZ - Repubblica Ceca 19
UZ - Uzbekistan 17
TH - Thailandia 15
MY - Malesia 14
CI - Costa d'Avorio 13
RS - Serbia 12
VE - Venezuela 12
CL - Cile 10
KE - Kenya 10
PT - Portogallo 10
ET - Etiopia 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 8
JO - Giordania 8
LT - Lituania 8
NZ - Nuova Zelanda 8
BO - Bolivia 7
DZ - Algeria 7
KZ - Kazakistan 7
EG - Egitto 6
HU - Ungheria 6
IR - Iran 6
RO - Romania 6
TN - Tunisia 6
AL - Albania 5
EU - Europa 5
JM - Giamaica 5
QA - Qatar 5
BH - Bahrain 4
CH - Svizzera 4
CR - Costa Rica 4
HR - Croazia 4
LB - Libano 4
PA - Panama 4
PE - Perù 4
SN - Senegal 4
EE - Estonia 3
NP - Nepal 3
PS - Palestinian Territory 3
UY - Uruguay 3
AO - Angola 2
BY - Bielorussia 2
DK - Danimarca 2
GA - Gabon 2
GR - Grecia 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
NO - Norvegia 2
OM - Oman 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
CM - Camerun 1
DM - Dominica 1
DO - Repubblica Dominicana 1
Totale 16.778
Salva come PNG Salva come JPEG
Città #
Singapore 1.067
Ashburn 852
Dublin 721
Chandler 627
San Jose 560
Hong Kong 429
Santa Clara 417
Dallas 395
Beijing 364
Ho Chi Minh City 263
Parma 232
Dearborn 220
Hanoi 204
Boardman 188
Johannesburg 167
Jacksonville 163
Ann Arbor 150
Nanjing 147
Lauterbourg 131
Los Angeles 117
Princeton 116
Shanghai 115
Izmir 108
Munich 107
Hefei 97
Wilmington 92
Milan 76
New York 72
Columbus 67
Helsinki 66
Seoul 66
Moscow 63
Vienna 56
São Paulo 53
Council Bluffs 51
Chicago 47
Bremen 46
Da Nang 44
Haiphong 44
Seattle 42
Shenyang 42
San Mateo 41
Bologna 39
Nanchang 38
Turku 38
London 36
Buffalo 35
The Dalles 35
Changsha 33
Groningen 33
Guangzhou 32
Kunming 32
Woodbridge 31
Frankfurt am Main 30
Hebei 30
Jakarta 30
Jiaxing 30
Orem 30
Des Moines 28
Tianjin 28
Toronto 28
Brooklyn 26
Brussels 26
Reggio Emilia 26
Rome 26
Warsaw 26
Houston 25
Jinan 25
Marseille 24
Tokyo 24
Falls Church 23
Stockholm 23
Amsterdam 22
Chennai 22
Sydney 22
Montreal 21
Ardea 20
Atlanta 19
Mexico City 19
Ferrara 18
Phoenix 18
Istanbul 17
Norwalk 17
Pune 16
Rio de Janeiro 16
San Francisco 16
Fremont 15
Hải Dương 15
Nuremberg 15
Abidjan 13
Grafing 13
Kocaeli 13
Manchester 13
Porto Alegre 13
Belo Horizonte 12
Bắc Ninh 12
Denver 12
Baghdad 11
Brno 11
Düsseldorf 11
Totale 10.257
Salva come PNG Salva come JPEG
Nome #
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 244
Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays 243
Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa 219
Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens 205
Opportunity and challenges of nasal powders: Drug formulation and delivery 197
Inhalable microparticles embedding calcium phosphate nanoparticles for heart targeting: The formulation experimental design 197
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro 191
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease 184
The Impact of Possible Misuses Conditions on in Vitro Performance of NEXThaler in Comparison with Ellipta Inhaler 181
CHIMERAL AGGLOMERATES OF MICRONIZED POWDER FOR NASAL ADMINISTRATION OF ANALGESIC DRUG 179
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant 175
Chimeral agglomerates of microparticles for the administration of caffeine nasal powders 171
Nebulizers effectiveness on pulmonary delivery of alpha-1 antitrypsin 170
Agglomerates of Morphine Microcrystals for Nasal or Buccal Administration 170
Solid-state characterization of tobramycin powders for inhalation 169
Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers 164
Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction 161
Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation 160
Therapeutic effect of cyclosporine A-loading TPGS micelles on a mouse model of LPS-induced neuroinflammation 157
Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients 154
Aerosolization performance of jet nebulizers and biopharmaceutical aspects 153
A Clinical Study of a Methacholine Dry Powder for the Bronchial Challenge Test 151
Polysaccharides: New Frontiers for Nasal Administration of Medicines 150
Respicell(TM): An innovative dissolution apparatus for inhaled products 150
A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide 149
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 149
Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers 148
A DRUG POWDER FOR INHALATION ADMINISTRATION AND PROCESS THEREOF 147
"Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs 146
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections 146
Crystalline Microparticles of a Beta-Agonist Coated with a Fatty Acid 144
High shear mixing of lactose and salmeterol xinafoate dry powder blends: biopharmaceutic and aerodynamic performances 144
Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery 144
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting 143
Dose administration manoeuvres and patient care in tobramycin dry powder inhalation therapy 143
Design and Characterization of Maltoheptaose-b-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen 139
Chimeral agglomerates of microparticles for nasal administration of analgesic drug powders 138
Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages 137
Crystallization of stable doped mannitol polymorphs and in vitro assessment of their safety as carriers for lung delivery 137
Nebulized coenzyme Q10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy 135
Caratterizzazione e modellazione del comportamento meccanicodella valvola di un pMDI. 134
Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation 132
Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure 131
Nasal delivery as a strategy for the prevention and treatment of COVID-19 131
Mannitol polymorphs as carrier in dpis formulations: Isolation characterization and performance 131
The use of multilayer poly(vinyl alcohol) adsorption to fabricate drug rich inhalable microparticles. 130
The role of airways microbiota on local and systemic diseases: a rationale for probiotics delivery to the respiratory tract 129
No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs 127
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 127
Characterisation of Particles Emitted from Two Formulations of Beclomethasone Dipropionate Solution Metered Dose Inhalers 127
Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways 126
Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency 126
Respirable amikacin dry powders for inhalation by a Quality bu Design procedure 125
Dry powder inhalation technology for heart targeting applied to calcium phosphate nanoparticles loaded with active substances 124
Evaluation of the Physico-mechanical Properties and Electrostatic Charging Behavior of Different Capsule Types for Inhalation Under Distinct Environmental Conditions 123
Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats 122
Dry Coating Technique for Inhalation Powders 122
Compositions in powder from made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation 121
Back to Basics: The development of a simple, homogenous, two-component dry powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. 121
No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs (vol 631, 122478, 2023) 120
The role of lipophilic adjuvant to produce high respirable tobramicin powders for inhalation 119
Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation 118
Sodium Hyaluronate Microparticles for Pulmonary Delivery of Anti-mycobacterial Drugs 118
Particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone having improved adhesion properties for powder formulations for inhalation 118
Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler® in Comparison with Diskus® and Turbohaler® Dry Powder Inhalers 118
Aerodynamic assessment for inhalation products: fundamentals and current pharmacopoeial methods 117
Layered lipid microcapsules for mesalazine delayed-release in children 116
Performance of Different Nebulizers in the Aerosolization of Colistimethate Sodium 116
Formulation Strategies for Antitubercular Drugs by Inhalation 115
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients 115
The development of amikacin dry powder for pulmonary administration 114
100 years of drug delivery to the lungs 113
AEROSOLIZED SULFATED HYALURONAN DERIVATIVES PROLONG THE SURVIVAL OF K18 ACE2 MICE INFECTED WITH A LETHAL DOSE OF SARS-COV-2 112
Particles and powders: Tools of innovation for non-invasive drug administration 112
Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction 112
Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the in Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler 111
POLVERI NASALI DI MORFINA PER UNA RAPIDA ANALGESIA 111
Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect 110
Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles 109
Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation 109
High Respirable Insulin Dry Powder for Pulmonary Administration 108
The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers 108
Inhalable spray-dried chondroitin sulphate microparticles: Effect of different solvents on particle properties and drug activity 107
Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis 107
The impact of lipid corona on rifampicin intramacrophagic transport using inhaled solid lipid nanoparticles surface-decorated with a mannosylated surfactant 106
Resistant tuberculosis: The latest advancements of second-line antibiotic inhalation products 106
Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake 105
Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam 105
Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations 105
Influence of Sodium Stearate on Amikacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis Patients with Pseudomonas Aeruginosa Lung Infections 104
The Influence of Energy Input During Dry Powder Blending on Dynamic Flow Properties, Powder Aerosolization and Dissolution of Dry Powders for Inhalation 103
Inhalable Microparticles Embedding Biocompatible Magnetic Iron-Doped Hydroxyapatite Nanoparticles 102
Drug Delivery Strategies for Pulmonary Administration of Antibiotics 102
chimerical agglomerates of microparticles for nasal administration of analgesic drug powders 102
The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery 101
INHALATION DRUG DELIVERY Techniques and Products 101
NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION 100
Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents 100
Curcumin and Quercetin-Loaded Lipid Nanocarriers: Development of Omega-3 Mucoadhesive Nanoemulsions for Intranasal Administration 99
Nanostructures for overcoming the pulmonary barrier: drug delivery strategies 99
Totale 13.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021114 0 0 0 0 0 0 0 0 0 36 55 23
2021/2022591 12 7 14 32 37 36 64 58 38 39 19 235
2022/20232.342 244 218 132 186 175 254 29 166 774 31 97 36
2023/20241.220 56 79 24 60 93 205 222 89 34 87 111 160
2024/20253.505 88 184 223 292 305 386 195 150 385 347 295 655
2025/20266.795 611 647 949 662 1.013 404 825 231 992 461 0 0
Totale 17.080